A COVID-19 Diagnosis Like an Avalanche Triggers a Series of Adverse Events but Saves a Life in the End
Abstract
1. Introduction
2. Case Presentation Section
3. Discussion
4. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Timmis, A.; Townsend, N.; Gale, C.P.; Torbica, A.; Lettino, M.; Petersen, S.E.; Mossialos, E.A.; Maggioni, A.P.; Kazakiewicz, D.; May, H.T.; et al. European society of cardiology: Cardiovascular disease statistics 2019. Eur. Heart J. 2020, 41, 12–85. [Google Scholar] [CrossRef]
- Ferlay, J.; Steliarova-Foucher, E.; Lortet-Tieulent, J.; Rosso, S.; Coebergh, J.W.W.; Comber, H.; Forman, D.; Bray, F. Cancer incidence and mortality patterns in Europe: Estimates for 40 countries in 2012. Eur. J. Cancer 2013, 49, 1374–1403. [Google Scholar] [CrossRef]
- Bayliss, E.A.; Reifler, L.M.; Zeng, C.; McQuillan, D.B.; Ellis, J.L.; Steiner, J.F. Competing Risks of Cancer Mortality and Cardiovascular Events in Individuals with Multimorbidity. J. Comorbidity 2014, 4, 29–36. [Google Scholar] [CrossRef]
- Meijers, W.C.; De Boer, R.A. Common risk factors for heart failure and cancer. Cardiovasc. Res. 2019, 115, 844–853. [Google Scholar] [CrossRef]
- Rinde, L.B.; Småbrekke, B.; Hald, E.M.; Brodin, E.E.; Njølstad, I.; Mathiesen, E.B.; Løchen, M.L.; Wilsgaard, T.; Brækkan, S.K.; Vik, A.; et al. Myocardial infarction and future risk of cancer in the general population—The Tromsø Study. Eur. J. Epidemiol. 2017, 32, 193–201. [Google Scholar] [CrossRef]
- Navi, B.B.; Reiner, A.S.; Kamel, H.; Iadecola, C.; Okin, P.M.; Elkind, M.S.V.; Panageas, K.S.; DeAngelis, L.M. Risk of Arterial Thromboembolism in Patients With Cancer. J. Am. Coll. Cardiol. 2017, 70, 926–938. [Google Scholar] [CrossRef]
- Curigliano, G.; Cardinale, D.; Dent, S.; Criscitiello, C.; Aseyev, O.; Lenihan, D.; Cipolla, C.M. Cardiotoxicity of anticancer treatments: Epidemiology, detection, and management. CA Cancer J. Clin. 2016, 66, 309–325. [Google Scholar] [CrossRef]
- Ananthan, K.; Lyon, A.R. The Role of Biomarkers in Cardio-Oncology. J. Cardiovasc. Transl. Res. 2020, 13, 431–450. [Google Scholar] [CrossRef]
- Paterson, D.I.; Wiebe, N.; Cheung, W.Y.; Mackey, J.R.; Pituskin, E.; Reiman, A.; Tonelli, M. Incident Cardiovascular Disease Among Adults With Cancer: A Population-Based Cohort Study. JACC CardioOncol. 2022, 4, 85–94. [Google Scholar] [CrossRef]
- Bell, C.F.; Lei, X.; Haas, A.; Baylis, R.A.; Gao, H.; Luo, L.; Giordano, S.H.; Wehner, M.R.; Nead, K.T.; Leeper, N.J. Risk of cancer after diagnosis of Cardiovascular Disease. JACC CardioOncol. 2023; in press. [Google Scholar] [CrossRef]
- Leiva, O.; AbdelHameid, D.; Connors, J.M.; Cannon, C.P.; Bhatt, D.L. Common Pathophysiology in Cancer, Atrial Fibrillation, Atherosclerosis, and Thrombosis: JACC: CardioOncology State-of-the-Art Review. JACC CardioOncol. 2021, 3, 619–634. [Google Scholar] [CrossRef]
- Kanth Manne, B.; Denorme, F.; Middleton, E.A.; Portier, I.; Rowley, J.W.; Stubben, C.; Petrey, A.C.; Tolley, N.D.; Guo, L.; Cody, M.; et al. Platelet gene expression and function in patients with COVID-19. Blood 2020, 136, 1317–1329. [Google Scholar] [CrossRef]
- Ranard, L.S.; Fried, J.A.; Abdalla, M.; Anstey, D.E.; Givens, R.C.; Kumaraiah, D.; Kodali, S.K.; Takeda, K.; Karmpaliotis, D.; Rabbani, L.R.E.; et al. Approach to Acute Cardiovascular Complications in COVID-19 Infection. Circ. Heart Fail. 2020, 13, 167–176. [Google Scholar] [CrossRef]
- Kuramoto, M.; Okada, M.; Saeki, H.; Yoshida, Y.; Hasegawa, S. Acute Myocardial Infarction Due to Coronary Occlusion Caused by a Metastatic Cardiac Tumor Arising from Squamous Cell Lung Cancer: An Evaluation with Three-dimensional Transthoracic Echocardiography. Intern. Med. 2022, 61, 345–350. [Google Scholar] [CrossRef]
- Liu, J.; Chen, H.; Xie, X.; Yang, Y.; Tang, S. Lung tumor presenting with acute myocardial infarction and lower extremity arterial embolism. BMC Cardiovasc. Disord. 2020, 20, 482. [Google Scholar] [CrossRef]
- Daher, I.N.; Luh, J.Y.; Duarte, A.G. Squamous cell lung cancer simulating an acute myocardial infarction. Chest 2003, 123, 304–306. [Google Scholar] [CrossRef][Green Version]
- Sławiński, G.; Jankowska, H.; Liżewska-Springer, A.; Lewicka, E. Effective cardioprotection with early initiation of sacubitril- valsartan in a patient with breast cancer and cancer treatment-induced heart failure. Kardiol. Pol. 2022, 78, 131–137. [Google Scholar] [CrossRef]
- McDonagh, T.A.; Metra, M.; Adamo, M.; Baumbach, A.; Böhm, M.; Burri, H.; Čelutkiene, J.; Chioncel, O.; Cleland, J.G.F.; Coats, A.J.S.; et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur. Heart J. 2021, 42, 3599–3726. [Google Scholar] [CrossRef]
- Daniele, A.J.; Gregorietti, V.; Costa, D.; Lopez-Fernandez, T. Use of emgliflozine in cardiotoxicity treatment. EMPACARD-treatment registry. Six-months follow-up. Eur. Heart J. 2022, 43, 2590. [Google Scholar] [CrossRef]
- Lyon, A.R.; López-Fernánde, T.; Couch, L.S.; Asteggiano, R.; Aznar, M.C.; Bergler-Klei, J.; Boriani, G.; Cardinale, D.; Cordoba, R.; Cosyns, B.; et al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur. Heart J. 2022, 43, 4229–4361. [Google Scholar] [CrossRef]
Laboratory Test Results | I | II | Normal Range |
---|---|---|---|
C-reactive protein (CRP) [mg/dL] | 2.51 | 7.21 | 0–0.5 |
D-dimers [ng/mL] | 648 | 4228 | 0–500 |
Troponin T [ng/L] | 628.5 | 14 | 0–14 |
Hemoglobin [g/dL] | 15.2 | 15.1 | 13.7–175 |
N-terminal prohormone of b-type natriuretic peptide (NT-proBNP) [pg/mL] | 2492.6 | 8163.1 | 0–125 |
Aspartate transaminase (AST) [U/L] | 64 | 36 | 5–34 |
Blood glucose [mg/dL] | 270 | 207 | 70–99 |
Glycated haemoglobin [%] | 11.2 | 10.8 | 4.8–5.9 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Iwański, M.; Sokołowska, A.; Wańczura, P.; Filipowska, J.; Styczkiewicz, K. A COVID-19 Diagnosis Like an Avalanche Triggers a Series of Adverse Events but Saves a Life in the End. Healthcare 2023, 11, 1847. https://doi.org/10.3390/healthcare11131847
Iwański M, Sokołowska A, Wańczura P, Filipowska J, Styczkiewicz K. A COVID-19 Diagnosis Like an Avalanche Triggers a Series of Adverse Events but Saves a Life in the End. Healthcare. 2023; 11(13):1847. https://doi.org/10.3390/healthcare11131847
Chicago/Turabian StyleIwański, Mateusz, Aldona Sokołowska, Piotr Wańczura, Justyna Filipowska, and Katarzyna Styczkiewicz. 2023. "A COVID-19 Diagnosis Like an Avalanche Triggers a Series of Adverse Events but Saves a Life in the End" Healthcare 11, no. 13: 1847. https://doi.org/10.3390/healthcare11131847
APA StyleIwański, M., Sokołowska, A., Wańczura, P., Filipowska, J., & Styczkiewicz, K. (2023). A COVID-19 Diagnosis Like an Avalanche Triggers a Series of Adverse Events but Saves a Life in the End. Healthcare, 11(13), 1847. https://doi.org/10.3390/healthcare11131847